Before patients ask me whether ketamine therapy will work for them, they almost always ask something else first:
"Doctor, will I get addicted?"
It's a reasonable question. Ketamine has a complicated public reputation. It's used in operating rooms around the world as one of the safest anaesthetics we have. It's also listed as a controlled substance because it can be — and is — misused recreationally. So when a patient hears that the same molecule is now being used to treat their depression, the first instinct is to pause.
You should pause. The question deserves a careful answer.
Here is the most honest one I can give:
ketamine, the molecule, has a known abuse potential. Ketamine, the supervised medical treatment, has a very different risk profile — and the difference between the two is almost entirely about how it is delivered, by whom, and under what protocol.
In other words: the answer to "is ketamine therapy addictive?" is not a yes or a no. It is it depends on the clinic. This article explains exactly what that means, so you can ask the right questions before you start.
Three very different things called "ketamine"
A lot of confusion comes from treating "ketamine" as one thing. It isn't. There are at least three completely different situations that get lumped together in headlines:
1. Recreational, street-source ketamine.
Unregulated supply. Unknown purity. Self-administered, usually intranasally ("snorting"), often in social settings, often in combination with alcohol or other substances. Doses are typically much higher than therapeutic doses, repeated frequently, and entirely unsupervised. This is the setting where ketamine addiction is a real and documented problem — and where the most serious long-term harms (bladder damage, cognitive effects, dependence) are seen.
2. At-home or telehealth-prescribed oral ketamine.
A growing market, especially in the United States. A patient has a video consultation, receives a prescription for sublingual ketamine lozenges, and self-administers them at home, often without direct medical supervision during the experience. The doses are clinical, but the structure around the medicine is much closer to "take a tablet" than "have a procedure." Risk sits in the middle — higher than supervised care, lower than recreational misuse — and it varies enormously depending on the prescribing protocol.
3. Supervised, in-clinic ketamine therapy.
What we provide at Mind Brain Institute and what most established psychiatric clinics provide. Administered by a clinician (intravenous infusion, intramuscular injection). Carefully dosed. Always observed. Always followed by an integration period before the patient leaves. No take-home medication. A defined treatment course, not an open-ended prescription.
These three situations share a molecule. They share almost nothing else.
When you read about "ketamine addiction" in the news, the story is almost always about situation 1, occasionally about situation 2, and almost never about situation 3. That distinction matters more than any other piece of information in this article.
The honest short version: in supervised clinical use, addiction has been remarkably rare.
The most cited review of this question is Schak et al. (2018), which examined the published cases of ketamine misuse arising from medical treatment over more than 30 years of use. The reviewers found that despite ketamine being administered to many thousands of patients in research and clinical settings, the documented cases of patients developing a substance use disorder as a result of treatment were strikingly few.
More recent monitoring data from established ketamine clinics — including multi-year follow-ups of patients on maintenance protocols — has continued to show very low rates of misuse, dependence, or craving when the treatment is delivered in a properly structured clinical setting.
This is not the same as saying the risk is zero. It isn't. Ketamine acts on the brain's reward circuitry, and any medicine that does so deserves vigilance. But the data, taken together, says something specific:
The addictive potential of ketamine appears to be activated mainly by the conditions of use — frequency, unsupervised access, escalating doses, and combining it with other substances — rather than by the clinical doses themselves.
That is a different message from either "it's completely safe" or "it's a recreational drug being repackaged." Both of those are wrong. The accurate version is that the molecule has potential, and the protocol is what determines whether that potential is expressed.
If you want a practical, clinician's-eye view of where ketamine-treatment addiction actually shows up, it concentrates in four places:
1. At-home protocols with weak supervision. The single biggest risk factor in the current landscape. If a patient is given a bottle of ketamine lozenges and told to take one when they feel low, the medicine is now functioning the way a recreational substance functions: self-administered, on demand, in response to mood. That is a very different psychological pattern from "I go to the clinic on a scheduled day, get treated, and leave."
2. Patients with active or recent substance use disorder. This is a screening issue. Patients with current alcohol use disorder, stimulant use disorder, opioid use disorder, or a recent history of ketamine misuse are at meaningfully higher risk and require either a different treatment plan or a much more structured one with addiction-medicine support built in.
3. Telehealth-only models with no in-person assessment. A first ketamine prescription issued after a 20-minute video call, without a thorough psychiatric history and without an in-person evaluation, is a setup that the medical community is, rightly, growing concerned about. Some patients in this model do fine. Others receive a powerful medicine without the safety net it deserves.
4. "As-needed" or open-ended prescribing. Ketamine should not be a PRN medication. The moment it becomes "take one when you feel bad," the structure that protects the patient is gone.
If you map those four risk factors against responsible in-clinic care, you can see why supervised clinical ketamine sits in a very different risk category: none of these four risk patterns apply.
This is the part most patients have never had explained to them, so it's worth being concrete. A clinic delivering ketamine therapy responsibly — whether ours or anyone else's — will have most of the following safeguards built in:
Defined induction phase. A specific number of sessions (usually 6–8) over a defined window (usually 2–4 weeks), with response assessed at the end. Not open-ended.
Supervised administration. Every dose is given in the clinic, observed by trained staff, with vitals monitored. You never handle the medicine yourself.No take-home prescriptions. You do not leave with ketamine. You do not have ketamine at home. The medicine and your access to it are entirely contained within the clinic environment.
Frequency limits. Even during the induction phase, sessions are spaced out — typically 2–3 times per week, not daily. Maintenance sessions, when used, are much further apart (every 2–6 weeks for some patients, monthly for others).Integration sessions. The hours after a ketamine session — when the brain is most receptive to new patterns — are used purposefully. This isn't "lie down and recover." It's a structured therapeutic conversation that helps the experience translate into change. Integration is part of why supervised ketamine works and part of why it doesn't become a habit-of-mood-management.
Structured tapers. When maintenance ends, it ends gradually and intentionally, not abruptly and not by patient request.
Ongoing screening. At every session, the clinician is watching for signs of craving, escalation requests, between-session use, or psychological dependence. If any of those appear, the protocol changes.
A patient asking "is ketamine therapy addictive?" is really asking, behind the words, "will the clinic protect me from this medicine if I can't protect myself?" A responsible clinic's answer to that question, in concrete protocol form, is the most important thing you can hear.
Honesty is part of safety. Ketamine isn't the right treatment for every patient, and a clinic that says it is should be approached cautiously.
The first conversation in our clinic is not about scheduling an infusion. It is about whether ketamine is right for you in the first place. For some patients the right answer is yes, and we proceed. For some it is "not yet," and we optimize medications, psychotherapy, or TMS first. For some it is "not this treatment," and we explain why.
If you would like a fuller picture of what to expect when you do start, the next article in this series — "What Does a Ketamine Session Actually Feel Like?" — walks through arrival, the session itself, and the hours after.
And if you're reading this because conventional antidepressants haven't worked for you, our article on "When Antidepressants Aren't Working" lays out the full clinical decision tree, with ketamine positioned alongside TMS and other options based on mechanism rather than hype.
You don't have to take a clinic's word for it. Ask:
"Will I receive ketamine in the clinic or at home?" (In-clinic is the safer answer for most patients starting out.)
"How many sessions does my induction protocol include, and how is response assessed?"
"What is your maintenance protocol if I respond?"
"Who supervises me during the session, and what monitoring is done?"
"What is your screening process — what would make you decline to treat me, or pause treatment?"
"What integration support do you offer between and after sessions?"
"What happens if I ask for sessions more often than your protocol allows?"
Any clinic that hesitates on these answers, or treats them as bureaucratic interference with treatment, is telling you something important.
Is ketamine therapy addictive?
The molecule has a known abuse potential. Ignoring that would be dishonest. So would catastrophizing it.
Used in a supervised clinical protocol, with proper screening, structured dosing, observed administration, no take-home medicine, integration support, and a clinician watching for the patterns that lead to misuse — the documented addiction risk is low, and has been low across decades of medical use.
Used outside that structure — at-home protocols with weak supervision, telehealth-only models, open-ended prescribing, or recreational settings — the risk profile changes substantially.
Asking the question is the right instinct. The answer depends less on whether ketamine is the right molecule for your depression, and more on whether the clinic you're considering has built the structure that makes the medicine safe.
If you're considering ketamine therapy for treatment-resistant depression, severe anxiety, suicidal ideation, or another condition where conventional treatment hasn't been enough — we'd encourage you to ask these questions of any clinic, including ours. The right clinic will welcome them.
Book an appointment with the top
Psychiatrist near you.
I have severe depression and anxiety. Is it possible to get ketamine assisted th... Read more
Which psychiatry clinic in Hyderabad providing Ketamine therapy for depression a... Read more
Suffering from Depression since i was 10. Things got out of hand when I was in c... Read more